Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9757394 | CMP DEV LLC | Spironolactone aqueous formulations |
Oct, 2036
(13 years from now) | |
US10493083 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
US10888570 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
US10660907 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
US10624906 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
US11395828 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
US11389461 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
US11491166 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) |
Market Authorisation Date: 04 August, 2017
Treatment: Carospir is indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure; C...
Dosage: SUSPENSION;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic